Goldshield management team outbids Fuhrer family
This article was originally published in Scrip
Executive Summary
Goldshield Group's management team has launched a counter-bid for the UK listed pharmaceuticals and consumer health group, offering a 2.2% premium to last week's offer from the family that owns Israel's Neopharm. The management team's bidding vehicle, Midas Bidco, is offering 460 pence per share in cash, valuing Goldshield at £169 million.